title: Immune signatures in human PBMCs of idiotypic vaccine for HCV-related lymphoproliferative disorders.
abstract: Hepatitis C virus (HCV) is one of the major risk factors for chronic hepatitis, which may progress to cirrhosis and hepatocellular carcinoma, as well as for type II mixed cryoglobulinemia (MC), which may further evolve into an overt B-cell non-Hodgkin's lymphoma (NHL). It has been previously shown that B-cell receptor (BCR) repertoire, expressed by clonal B-cells involved in type II MC as well as in HCV-associated NHL, is constrained to a limited number of variable heavy (VH)- and light (VL)-chain genes. Among these, the VK3-20 light chain idiotype has been selected as a possible target for passive as well as active immunization strategy. In the present study, we describe the results of a multiparametric analysis of the innate and early adaptive immune response after ex vivo stimulation of human immune cells with the VK3-20 protein. This objective has been pursued by implementing high-throughput technologies such as multiparameter flow cytometry and multiplex analysis of cytokines and chemokines.
authors.affiliation: Lab, of Molecular Biology and Viral Oncogenesis & AIDS Reference Center, Istituto Nazionale Tumori "Fond, G, Pascale", Naples, Italy. irccsvir@unina.it.
authors.forename: Luigi
authors.initials: L
authors.lastname: Buonaguro
authors.forename: Annacarmen
authors.initials: A
authors.lastname: Petrizzo
authors.forename: Marialina
authors.initials: M
authors.lastname: Tornesello
authors.forename: Maria
authors.initials: M
authors.lastname: Napolitano
authors.forename: Debora
authors.initials: D
authors.lastname: Martorelli
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Castello
authors.forename: Gerardo
authors.initials: G
authors.lastname: Beneduce
authors.forename: Amalia
authors.initials: A
authors.lastname: De Renzo
authors.forename: Oreste
authors.initials: O
authors.lastname: Perrella
authors.forename: Luca
authors.initials: L
authors.lastname: Romagnoli
authors.forename: Vitor
authors.initials: V
authors.lastname: Sousa
authors.forename: Valli
authors.initials: V
authors.lastname: De Re
authors.forename: Riccardo
authors.initials: R
authors.lastname: Dolcetti
authors.forename: Franco M
authors.initials: FM
authors.lastname: Buonaguro
mesh_terms: D056704:Adaptive Immunity / Q000502:physiology; D001402:B-Lymphocytes / Q000276:immunology; D015415:Biomarkers / Q000378:metabolism; D002478:Cells, Cultured; D016207:Cytokines / Q000276:immunology; D016174:Hepacivirus / Q000276:immunology; D006526:Hepatitis C / Q000150:complications / Q000276:immunology / Q000821:virology; D006801:Humans; D007113:Immunity, Innate / Q000502:physiology; D007130:Immunoglobulin Idiotypes / Q000276:immunology*; D007135:Immunoglobulin Variable Region / Q000276:immunology*; D007963:Leukocytes, Mononuclear / Q000166:cytology / Q000276:immunology / Q000821:virology; D008232:Lymphoproliferative Disorders / Q000209:etiology / Q000276:immunology / Q000821:virology; D010641:Phenotype; D011947:Receptors, Antigen, B-Cell / Q000737:chemistry / Q000276:immunology*; D014765:Viral Vaccines / Q000276:immunology*
chemical_list: D015415:Biomarkers; D016207:Cytokines; D007130:Immunoglobulin Idiotypes; D007135:Immunoglobulin Variable Region; D011947:Receptors, Antigen, B-Cell; D014765:Viral Vaccines